News

Saama Sales Operations Solution for Life Science is an integrated data and analytics platform that supports the drug commercialization process by automating sales operations and analytics. As part

BHV is a privately held pharmaceutical company developing the SGLT2 inhibitor remogliflozin etabonate (remogliflozin) for type 2 diabetes and non-alcoholic steatohepatitis (NASH). Remogliflozin is currently in Phase II

This facility has been reconfigured to provide for 30 semi-private rooms to give each clinical trial volunteer a more comfortable experience for extended in-house stays. This dedicated clinical

The trial will assess the clinical effects of riociguat in patients with pulmonary arterial hypertension (PAH) who show an insufficient response to treatment with phosphodiesterase-5 inhibitors (PDE-5i) either

The deal will see MedImmune contribute both funding and a post-doctoral scientist to work within the laboratory of Professor Kevin Brindle at the University of Cambridge in the

The product is a component of the contingent rights the company received in connection with its acquisition of a portfolio of ophthalmic products from Fera Pharmaceuticals and its

The company is exclusively manufacturing the approved hemophilia A therapy drug Kogenate FS/Kogenate Bayer at its Berkeley facility in California. According to Bayer, establishing an additional supply source

XARTEMIS XR’s release profile combines Mallinckrodt’s newly patented technology, including design, formulation, pharmacokinetic and release characteristics, and Depomed’s advanced Acuform drug delivery technology. The drug is the first

Qudexy XR is indicated as initial monotherapy in patients ten years of age and older with POS or primary generalized tonic-clonic seizures. The once-daily, broad-spectrum antiepileptic drug is